E-series resolvins are biosynthesized from eicosapentaenoic acid during the resolution phase of acute inflammation and enhance inflammation resolution. However, the role of E-series resolvins in inflammation resolution is not yet known. Herein, we show that in human polymorphonuclear neutrophils (PMNs), resolvin E1 (RvE1) selectively enhances reactive oxygen species (ROS) generation induced by N-formylmethionyl-leucyl-phenylalanine. The RvE1-mediated enhancement is eliminated by a pan-antagonist of leukotriene B4 (LTB4) receptors, LY255283, or an NADPH oxidase inhibitor, diphenyleneiodonium. Thus, RvE1 enhances NADPH oxidase-mediated ROS generation via LTB4 receptors. Unlike RvE1, resolvins E2 and E3 do not show such activation of PMNs. Our findings suggest that RvE1 contributes to regulation of ROS generation, in accordance with the inflammatory state of the host.
RvE2, and RvE3) are biosynthesized from x-3 PUFAs eicosapentaenoic acid (EPA) during the resolution phase of acute inflammation; these subsequently enhance inflammation resolution [3] [4] [5] [6] [7] . They act within a local inflammatory milieu to stop leukocyte recruitment and promote the resolution of inflammation [4, 5, 7] .
Neutrophils have a variety of complex antimicrobial functions, including not only chemotaxis and phagocytosis, but also the destruction of targeted invaders, such as bacteria, using proteases, antimicrobial peptides, other antimicrobial endogenous agents, and, most notably, reactive oxygen species (ROS) [8] . In the neutrophils, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase is the enzyme that produces superoxide anions, leading to the production of other ROS, i.e., hydrogen peroxide, hydroxyl radicals, and hypochlorous acid, which all contribute to the death and destruction of the bacteria within the phagosome [9] . ROS production is induced by several agonists such as interleukin (IL)-8, phorbol 12-myristate 13-acetate (PMA), N-formylmethionyl-leucyl-phenylalanine (fMLF), and yeast-derived particles, zymosan [9, 10] . For full activation of ROS production, neutrophils require other preactivators prior to receiving the inducing signals derived from the agonists [9] . The preactivators alone induce either a very weak or no response for ROS production [9] . However, preactivators such as lipopolysaccharide (LPS), tumor necrosis factor (TNF)-a, and granulocytecolony-stimulating factor enhance the activity of NADPH oxidase, thus inducing stronger activation of the ROS production process [9] . Tyrosine phosphorylation plays an important role in the activation signal derived from the preactivators [9] . Kebir et al. reported that RvE1 promotes phagocytosis-induced ROS generation through NADPH oxidase in human polymorphonuclear neutrophils (PMNs) [2] . These lines of evidence support the hypothesis that E-series resolvins function as preactivators in PMNs. However, the preactivation roles of individual E-series resolvins in the process of inflammation, as well as the molecular mechanism by which E-series resolvins promote ROS generation with the cooperation of the inducers, have not yet been fully clarified.
In this study, we compared the preactivation effects of E-series resolvins on ROS production in response to several soluble agonists such as IL-8, PMA, and fMLF. We showed that synthetic RvE1 promotes fMLF-induced ROS generation in PMNs, while synthetic RvE2 and E3 do not. Our findings suggest a role for RvE1 in the functional regulation of PMNs via ROS generation, in accordance with the inflammatory state of the host organisms.
Materials and methods

Reagents and antibodies
Dulbecco's modified Eagle's medium (DMEM) without phenol red was obtained from Nissui Pharmaceutical Co. (Tokyo, Japan). The fluorescein conjugate formylNle-Leu-Phe-Nle-Tyr-Lys (abbreviated as FITC-fMLF) was obtained from Thermo Fisher Scientific Inc. (Waltham, MA, USA). Luminol, isoluminol, and L-glutamine were purchased from Tokyo Chemical Industry (Tokyo, Japan). N-Formyl-Met-Leu-Phe (fMLF, F3506) and PMA were from Sigma-Aldrich (St. Louis, MO, USA). Horseradish peroxidase (HRP) was obtained from Fujifilm Wako Pure Chemical Corporation (Osaka, Japan). Diphenyleneiodonium chloride was obtained from Cayman Chemical (Ann Arbor, MI, USA). Recombinant human TNF-a was purchased from PeproTech EC (London, UK). Recombinant human IL-8 (208-IL-010) was from R&D Systems (Minneapolis, MN, USA). All reagents used were of the highest grade available from commercial sources. RvE1, RvE2, and RvE3 were synthesized in-house [11, 12] and preserved as ethanol solutions.
Isolation of PMNs
Human PMNs were isolated from the peripheral venous blood of healthy volunteers according to Ono et al. [10] . Whole blood (20 mL) was then mixed with 7 mL of a 6% dextran solution and 15 mL of HBSS and allowed to stand for 30 min at room temperature until stratification occurred. The upper leukocyte-rich plasma layer was transferred to a new tube containing endotoxin-free Ficoll-Paque Plus gradient (GE Healthcare Japan, Tokyo, Japan) and was centrifuged (400 g, 30 min, 22°C). The cell pellet was treated with deionized water for 30 s and centrifuged (400 g, 5 min, 22°C). Contaminating erythrocytes were removed using two cycles of hypotonic lysis. Finally, the cells were resuspended in a small volume of HBSS, and the purity of the cells was determined by light microscopic assessment with trypan blue exclusion staining. PMNs were only used in experiments if the viability was 99% or more and the purity was at least 95%. The cells were diluted to densities of 1 9 10 7 cellsÁmL À1 with HBSS for the chemiluminescence (CL) assay and flow cytometry assays, as described below. All volunteers were healthy adults, 30-61 years of age, who were informed of the purpose of these experiments. Informed consent was obtained for experimentation with human subject, and all procedures were performed in compliance with relevant laws and institutional guidelines. The protocol was approved by the Ethical Review Committee at the Teikyo University School of Medicine (no. 15-192-2) .
Detection of ROS: CL assay
The total ROS and superoxides by PMNs were analyzed using two methods: luminol/isoluminol-dependent CL assay and flow cytometry assays using the ROS-ID Ò Total ROS/Superoxide detection kit (Enzo Life Sciences, Farmingdale, NY, USA). The CL assays were performed by using isolated PMNs according to Ono et al. [10] . PMNs were maintained in DMEM supplemented with 2% human serum and without phenol red (medium A . The amounts of extracellular and intracellular ROS were measured using the luminol-enhanced CL method [9, 10] . The amount of extracellular CL was determined using the isoluminol-enhanced CL method containing HRP (>8 UÁmL À1 ) [13] .
Detection of ROS: flow cytometry
Intracellular ROS levels were measured by flow cytometry using the Total ROS/Superoxide detection kit (Enzo Life Sciences Inc.), according to the manufacturer's instructions. PMNs (2 9 10 5 cells) were pre-treated with 0.5 mL medium A containing 0.1% ethanol as a control or RvE1 in 0.5 mL medium A containing 0.1% ethanol for at least 15 min prior to the addition of the ROS/superoxide detection regents, after which the PMNs were incubated at 37°C for 45 min in the dark. Finally, the ROS inducer 0.5 lM fMLF solution was added, and the mixture was incubated at 37°C for another 45 min in the dark. The samples were analyzed with a FACSCanto II (Becton Dickinson, Franklin Lakes, NJ, USA) and analyzed using FLOWJO software (Treestar, Inc., San Carlos, CA, USA).
Determination of the fMLF receptor
Fluorescein isothiocyanate (FITC) can be used to investigate the fMLF receptors by flow cytometry according to Schneider et al. [14] . As such, the effects of RvE1 on the expression level of the fMLF receptor was investigated by flow cytometry using FITC-fMLF. PMNs (2 9 10 5 ) were pre-incubated with either medium A containing 0.1% ethanol or 300 nM RvE1 in medium A containing 0.1% ethanol for 60 min at 37°C. The cells were then incubated in the . The integral responses of the CL were recorded at 37°C for 10 min by a luminometer. ROS production is presented as a percentage of the integrated CL in the PMNs treated with test samples versus those treated with ethanol. All experiments were repeated at least five times on different donors, and the results are presented as the mean AE SEM. **P < 0.01, ***P < 0.005 (compared with human PMNs treated with ethanol). It is noted that EPA, a source in E-series resolvin biosynthesis, did not enhance fMLF-induced ROS production even in the concentration range of 30-1000 nM under the experimental conditions. absence or presence 10 lM fMLF for 15 min on ice, followed by further incubation of the PMNs with 10 nM FITC-fMLF for 30 min on ice. The PMNs were washed twice with cold PBS (À) and then suspended in 0.5 mL of cold PBS (À) and immediately put on ice. The samples were analyzed with a FACSCanto II and with FLOWJO software. The fluorescence intensity of the cells was measured with a flow cytometer, and the data were presented as mean fluorescence intensities (MFIs).
Statistical analysis
The results are expressed as mean AE standard error of mean (SEM). The program PRISM 6 (Graph Pad Software, Inc., San Diego, CA, USA) was used to perform the statistical analysis. Comparisons between groups were performed by a one-way analysis of variance and Dunnett post-test. Differences were considered significant when P < 0.05.
Results
Comparative preactivation effects of RvE1, RvE2, and RvE3 on ROS production in PMNs
To compare the preactivation effects of E-series resolvins (RvE1, RvE2, and RvE3) on ROS production in PMNs, PMNs were preincubated with each E-series resolvin at a concentration of 300 nM for 60 min, followed by stimulation with one of the several inducers, fMLF, IL-8, or PMA. The amount of ROS was measured using the luminol-enhanced CL method, which sensitively detects both extracellular and intracellular ROS [9, 10] . As shown in Fig. 1 , only the combination of the RvE1 pretreatment and fMLF induction significantly increased ROS production in PMNs, as compared with the control treatments. RvE2 and RvE3 showed no obvious promotion effects on the fMLF- induced ROS generation ( Figs 1A and 2A) . None of the E-series resolvins promoted ROS generation induced by either IL-8 and PMA (Fig. 1B,C) . Furthermore, none of the E-series resolvins alone directly activated ROS production over a range of concentrations (30-1000 nM) without the agonist induction under our experimental conditions (data not shown). The preactivation effect of RvE1 on PMNs was concentrationdependent and time-dependent ( Fig. 2A-C) . It was detected at a concentration of 100 nM. The fMLFinduced ROS production reached a maximum level at 3.7 AE 0.1 min after the addition of fMLF. Additional treatment with RvE1 did not affect the timing of ROS generation (Fig. 2B) . However, prolonging the time of pretreatment with RvE1 increased the ROS production (Fig. 2C ).
RvE1 enhances NADPH oxidase derived ROS generation through the leukotriene B4 receptor
To reveal a detailed mechanism of the RvE1 preactivation effects, PMNs were exposed to RvE1 along with an NADPH oxidase inhibitor, diphenyleneiodonium (DPI), or the LTB4 receptor antagonist LY255283 (Fig. 2D) . The LTB4 receptors consist of at least two sub-types, type 1 (BLT1) and type 2 (BLT2). BLT1 is reported to be one of the cell-surface receptors to which RvE1 directly binds [15] . LY255283 reduced the level of ROS production to the level of fMLF-induced ROS production without RvE1 treatment. However, when LY255283 was added just before fMLF stimulation, it did not affect the preactivation effects of RvE1 (Fig. S1 ). These results indicate that LY255283 abolished only the RvE1-mediated enhancement of the fMLF-induced ROS generation. On the other hand, DPI eliminated ROS production. These results suggest that the LTB4 receptors are involved in the RvE1 preactivation, whereas NADPH oxidases play a key role in cellular ROS generation, as previously reported [2] . In the experimental methods using luminol-enhanced CL method, both intracellular and extracellular ROS are detected because luminol permeates the cells [16] . Using isoluminol-enhanced CL method, only extracellular ROS is detectable [13] . Experiments by the isoluminol-enhanced CL method demonstrated that the extracellular ROS amount produced by RvE1-treatments is insignificant, as shown in Fig. 3 . These results indicated that the promoting by RvE1 on the ROS production in PMNs occurred almost intracellularly. Using FACS, we therefore focused on the analyses of the production of intracellular ROS and/or nitrogen species in PMNs treated with RvE1. We used two specific fluorescent probes: orange (550/620 nm) for the detection of superoxides and green (490/525 nm) for the detection of a wide range of reactive species (total ROS), such as hydrogen peroxide, peroxynitrite, and hydroxyl radicals. FACS analysis showed that additional treatment with RvE1 to fMLF significantly increased the population of cells with enhanced amounts of both superoxide and total ROS (Q2) as compared with the case using the fMLF alone. The treatment with RvE1 alone, however, did not affect the population of Q2 cells, as compared with the mock treated cells (Fig. 4A,C) . In contrast, the cell population with only an increase in superoxide (Q1) quantity was not affected by the combinational treatment with fMLF and RvE1, in contrast to the case using fMLF alone (Fig. 4A,B) . The cell population displaying only an increase in total ROS (Q3) was also unaffected (Fig. 4A) . Under the experimental conditions, the cell population in the normal state (Q4) was significantly reduced by the treatment of RvE1 in addition to the fMLF treatment, as compared with fMLF alone (Fig. 4A) . Thus, these results suggest that RvE1 promotes the fMLF-induced generation of a wide range of intracellular ROS, including superoxide, in PMNs.
RvE1 has no influence on the binding of fMLF to neutrophils
The fMLF receptors expressed on the surface of the PMNs respond to bacterial N-formyl peptides. This triggers not only the migration of PMNs to the site of bacterial invasion, but also the initiation of an activation pathway for the production of oxidative species. Therefore, we next examined whether RvE1 impacted the binding ability of fMLF to PMNs by using the fluorescent agonistic formyl peptide receptor (FPR) ligand, FITC-fMLF. FITC-fMLF has been shown to be useful for the analysis of the receptors' alterations in terms of binding, structure, expression, distribution, and internalization [17] . PMNs were treated with 10, 100, and 1000 nM FITC-fMLF solutions for 30 min on ice, and the fluorescence intensity of the PMNs was measured. The results show that the amount of the FITC-fMLF binding to the PMNs increased in a dosedependent manner (Fig. S2) . In addition, the FITCfMLF binding was remarkably eliminated in the presence of a 1000-fold molar excess of fMLF (Fig. 5A,C) ; this suggests that the binding activity of the fluorescent FPR ligand is specific to the fMLF receptors (Fig. 5A,  C) . Under these conditions, treatment with RvE1 did not affect the binding ability of the PMNs to FITCfMLF, as compared with the mock treatment (Fig. 5B,  C) . On the other hand, TNF-a increased the binding ability of the PMNs to FITC-fMLF (Fig. 5C) . Thus, these results show that RvE1 did not modify the ability of PMNs to bind to fMLF.
Discussion
Previous studies using mouse models have shown the biosynthesis of E-series resolvins (RvE1, RvE2, and RvE3) from EPA during the resolution phase of acute inflammation, which thereby promotes inflammation resolution [3] [4] [5] [6] [7] . However, the role of individual E-series resolvins in inflammation resolution and the molecular mechanism by which they promote it have not yet been fully clarified. In this study, we demonstrated that RvE1 enhanced fMLF-induced ROS generation in PMNs, but RvE2 and RvE3 did not. In addition, the results by isoluminol-enhanced CL method showed that the ROS generation by the promoting effect of RvE1 in PMNs observed in the cells, but not outside the cells (Fig. 3) . Excess extracellular ROS can lead to tissue damage, and the PMN functions must be appropriately regulated in order to achieve host defense and avoid tissue-damaging inflammation [13] . At this point, the activation of PMNs induced by RvE1 would be regulated in the host organism. A previous report showed that RvE1 enhanced phagocytosis-induced ROS generation and modulated the balance of apoptotic and anti-apoptotic signals in human neutrophils [2] . Furthermore, Kettritz et al. [18] demonstrated that fMLF-stimulated PMNs undergo apoptosis by a superoxide-release-dependent pathway. These results suggest that, RvE1 enhances fMLF-induced ROS generation in human neutrophils, and as a result may control the PMN functions in acute inflammation through antimicrobial activity and apoptotic/anti-apoptotic regulatory activity. RvE1 may work as a modulator of neutrophil apoptosis, an important control point of the resolution of inflammation. Further studies are necessary to understand the correlation between the RvE1-promoted ROS generation and RvE1-mediated apoptotic regulation. As a preactivator, TNF-a can cooperate with all three inducers, namely fMLF, IL-8, and PMA, to enhance ROS production (Fig. 1) . It increases the expression of the fMLF receptor on the cell surface of neutrophils such that the neutrophils efficiently capture the signal mediator of fMLF, as well as other preactivators such as TNF-a (Fig. 5) , granulocyte macrophage colony stimulating factor, and LPS [9] . In contrast, our results show that RvE1 selectively enhanced fMLF-induced ROS generation (Fig. 1) . RvE1 did not obviously affect the binding ability of PMNs to fMLF (Fig. 5) . These findings suggest that RvE1 enhances PMN activation in a manner different from that involving other preactivators. RvE1 is likely to contribute to the fine control of the ROS generation, in accordance with the inflammatory state of the host organism.
We demonstrated that the RvE1 preactivation was nullified by the LTB4 receptor antagonist LY255283 in PMNs (Fig. 2D) . LY255283 was originally developed to inhibit LTB4 receptor BLT1 [19, 20] , but it was found to inhibit both LTB4 receptors BLT1 and BLT2. Competitive binding assays using recombinant BLT1 and BLT2 revealed that LY255283 is a noncompetitive antagonist for BLT1 and a competitive antagonist for BLT2. Furthermore, it inhibits both the BLT1-and BLT2-dependent calcium mobilization of Chinese hamster ovary (CHO) cells expressing BLT1 and BLT2 [20, 21] . Therefore, LY255283 is likely to abolish the RvE1 preactivation of PMN activation by inhibiting LTB4 receptors, although it is unclear whether BLT1 or BLT2 plays a major role in the activation. BLT1 and BLT2 are expressed in PMNs, but chemerin receptor 23 (ChemR23), a G protein coupled receptor that is triggered the ligands chemerin and RvE1, was not detected with the protein levels (Fig. S3) [2, 22] . Arita et al. [15] reported that RvE1 could interact with BLT1 and ChemR23, but not with BLT2. These results suggest that BLT1 may be a key factor in the preactivation of RvE1 that enhances fMLF-induced ROS generation in PMNs.
In studies using mouse models, it was shown that all three E-series resolvins promotes inflammation resolution [3] [4] [5] [6] [7] . In our experiments using human PMNs, however, synthetic RvE2 and RvE3 exhibit no obvious preactivation effects when co-using fMLF, IL-8, and PMA as inducers, despite RvE1 acting as a preactivator for the fMLF-induced PMN activation (Fig. 1) . This suggests that the molecular mechanisms of RvE2 and RvE3 are distinct from those of RvE1 when acting as preactivators. There is a possibility that RvE2 and RvE3 may act as preactivators in pairs with unknown inducers (or in different cells). Further studies are necessary for the detailed molecular mechanisms to clarify.
In conclusion, the novel finding of the present study is that RvE1, promotes fMLF-induced and NADPH oxidase derived ROS generation in PMNs via the LTB4 receptor. The inducer fMLF, a major physiological chemotactic peptide derived from the bacterial cell wall, has been widely used as a model for N-formyl peptide mediated activation of neutrophils. To our knowledge, this is the first study to investigate the biological activity of RvE1 in the fMLF-mediated activation of phagocytic cells such as neutrophils and macrophages. The present study using human PMNs reveals a role of RvE1 in the active inflammation resolution process of the host organism. 
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